VBI Vaccines Inc (NASDAQ:VBIV)’s share price dropped 5.9% during mid-day trading on Wednesday . The stock traded as low as $0.62 and last traded at $0.64, approximately 568,983 shares were traded during trading. A decline of 46% from the average daily volume of 1,055,704 shares. The stock had previously closed at $0.68.

VBIV has been the subject of several research reports. ValuEngine raised VBI Vaccines from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research raised VBI Vaccines from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a report on Thursday, May 9th. BMO Capital Markets dropped their target price on VBI Vaccines to $5.00 and set an “outperform” rating for the company in a report on Tuesday, June 18th. Finally, Oppenheimer set a $5.00 target price on VBI Vaccines and gave the stock a “buy” rating in a report on Wednesday, June 19th.

The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.94 and a current ratio of 1.99. The stock has a market capitalization of $63.39 million, a P/E ratio of -0.67 and a beta of 0.41. The firm has a fifty day simple moving average of $0.83.

VBI Vaccines (NASDAQ:VBIV) last posted its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.02. VBI Vaccines had a negative return on equity of 71.46% and a negative net margin of 1,582.45%. The company had revenue of $0.64 million during the quarter, compared to the consensus estimate of $0.60 million. On average, research analysts forecast that VBI Vaccines Inc will post -0.43 EPS for the current year.

In other news, major shareholder Life Sciences Maste Perceptive bought 1,000,000 shares of the company’s stock in a transaction dated Monday, June 17th. The stock was bought at an average price of $0.62 per share, with a total value of $620,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jeff Baxter bought 144,000 shares of the company’s stock in a transaction dated Wednesday, June 19th. The shares were purchased at an average cost of $0.73 per share, with a total value of $105,120.00. Following the acquisition, the chief executive officer now directly owns 458,255 shares of the company’s stock, valued at approximately $334,526.15. The disclosure for this purchase can be found here. Insiders have bought 1,160,000 shares of company stock valued at $739,600 in the last three months. Insiders own 10.50% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. increased its position in shares of VBI Vaccines by 2,089.1% in the second quarter. BlackRock Inc. now owns 4,224,285 shares of the biopharmaceutical company’s stock worth $4,943,000 after purchasing an additional 4,031,318 shares during the period. General American Investors Co. Inc. increased its position in shares of VBI Vaccines by 23.2% in the second quarter. General American Investors Co. Inc. now owns 2,174,264 shares of the biopharmaceutical company’s stock worth $2,544,000 after purchasing an additional 409,800 shares during the period. Vanguard Group Inc. increased its position in shares of VBI Vaccines by 12.4% in the second quarter. Vanguard Group Inc. now owns 1,356,944 shares of the biopharmaceutical company’s stock worth $1,587,000 after purchasing an additional 149,690 shares during the period. Fosun International Ltd increased its position in shares of VBI Vaccines by 43.6% in the second quarter. Fosun International Ltd now owns 1,051,126 shares of the biopharmaceutical company’s stock worth $1,156,000 after purchasing an additional 319,045 shares during the period. Finally, Millennium Management LLC increased its position in shares of VBI Vaccines by 381.9% in the fourth quarter. Millennium Management LLC now owns 757,028 shares of the biopharmaceutical company’s stock worth $1,211,000 after purchasing an additional 599,934 shares during the period. Institutional investors own 46.03% of the company’s stock.

VBI Vaccines Company Profile (NASDAQ:VBIV)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Featured Article: Portfolio Manager

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.